Introduction
Tiotropium bromide is an anticholinergic drug, categorized as a long-acting muscarinic antagonist (LAMA) or long-acting anticholinergic bronchodilator. 1 These drugs are used primarily in the management of chronic obstructive pulmonary disease (COPD), but interest in LAMA for the treatment of asthma has increased in recent years, particularly for patients whose asthma is poorly controlled with inhaled corticosteroids (ICS) and long-acting β 2 agonists (LABA). [1] [2] [3] [4] Despite clear guidelines and a range of available treatments, at least 50% of asthma patients continue to experience poor control of their current symptoms or future exacerbations, which significantly compromises the patient's quality of life and places considerable strain on health care systems. 1, 4 Thus, there is a need for additional therapeutic options.
The mechanisms by which LAMA have the potential to improve asthma control have recently been reviewed. 1 Briefly, LAMA may: induce bronchodilation, or inhibit cholinergically-mediated bronchoconstriction, and with regular use inhibit the airway smooth muscle hypertrophy and hyper-responsiveness characteristic of chronic asthma; reduce cholinergically-mediated mucus secretion and inhibit goblet cell hyperplasia and mucus gland hypertrophy; and moderate leukocyte responses in the lower airways as well as proinflammatory gene expression by airway smooth muscle and bronchial epithelium. In addition, LAMA such as tiotropium may act as steroid-sparing agents in patients with severe or poorly controlled asthma, 5, 6 which may alleviate some of the burden of corticosteroid use on health-related quality of life in these patients. 7 A formulation of tiotropium delivered by soft mist inhaler has recently been approved in the UK 8 and in several other countries for add-on maintenance therapy in adults with asthma, specifically for patients who are currently treated with ICS and LABA yet experienced at least one severe exacerbation in the past year. Regulatory approval was based on the results of randomized controlled trials (RCTs) in patients with asthma which showed that addition of tiotropium to the existing controller regimen (ICS ± LABA) improved lung function, 2, 3, [9] [10] [11] [12] [13] and may improve symptom control 3, 11, 13 and lower the patient's exacerbation risk, 3 although it did not alter the use of rescue medications such as short-acting β 2 agonists (SABAs). 2, 3, 10, 13 However, these RCTs involved highly selected patient populations (for example, nonsmokers with no serious comorbidities) managed in tightly controlled settings, in most cases with relatively small patient numbers and short study periods. 2, [9] [10] [11] [12] [13] Their broader applicability requires the support of clinical studies that better represent real-life populations and situations.
14 Clinical studies on the effectiveness of LAMA as add-on therapy in real-life asthma care are still needed.
To that end, we examined the clinical effects of add-on therapy with tiotropium in a diverse group of over 2,000 asthma patients treated in UK primary care practice. Study patients were at least 18 years of age and had a physician-recorded diagnosis of asthma; patients with a recorded diagnosis of COPD were excluded, but no other clinically relevant exclusions were applied. By comparing exacerbation rates and other measures of asthma control in the year before and after the addition of tiotropium to the patient's asthma regimen, our goal was to determine whether the addition of LAMA improves asthma control in routine clinical practice.
Materials and methods
This historical, observational study of UK asthma patients used data obtained from the Optimum Patient Care Research Database (OPCRD; http://www.optimumpatientcare.org), which contains more than 5 million anonymized, longitudinal patient records from approximately 400 participating medical practices in the UK and is focused on patients with evidence of respiratory disease. The OPCRD has been approved by the Trent Multicentre Research Ethics Committee for use in clinical research, and the protocol for this study was approved by the Anonymised Data Ethics Protocols and Transparency Committee, which is the independent scientific advisory committee for the OPCRD.
Data were examined for the period 2001-2013. The medical record of each study patient was examined for the 12 months before (baseline) and 12 months after (outcome) the date of the patient's first prescription for tiotropium (index prescription date); hence, the index prescription dates spanned 2002-2012. Other LAMA drugs became available in the UK towards the end of the study period, but in the interest of investigating LAMA use in as many asthma patients as possible while using well-defined criteria, we limited the index prescription to tiotropium.
Two formulations of tiotropium bromide for inhalation were available in the UK during the study period: a drypowder inhaler with a recommended dosage of 10 µg (the dose delivered from one 18 µg capsule) once a day 15 and a soft mist inhaler with a recommended dosage of 5 µg (two puffs of 2.5 µg) once a day. 8 Although equivalence data are not yet available for patients with asthma, these formulations and dosages have comparable bronchodilator efficacy in patients with COPD, 16 ,17 so we chose to study the patients as a group, regardless of formulation/dosage.
The study patients had at least one prescription for tiotropium during the study window, had a recorded diagnosis of asthma, had no recorded diagnosis of COPD, were at least 18 years of age at the index prescription date, and had two continuous years of data (12 months each of baseline and outcome data). Figure 1 illustrates the patient selection process and study design. Figure 1 Patient selection process and study design. inclusion criteria: (A) at least one prescription for tiotropium, (B) recorded diagnosis of asthma, (C) no recorded diagnosis of cOPD, (D) at least 18 years of age at first tiotropium prescription, and (E) full 12 months of data before (baseline) and after (outcome) first tiotropium prescription. Abbreviation: cOPD, chronic obstructive pulmonary disease.
effectiveness measures
The baseline year was used for patient characterization and the outcome year for evaluation of asthma-related effectiveness measures. A complete list of the baseline variables examined is provided in the Supplementary materials (Table S1 ), along with their definitions and methods of calculation.
The effectiveness measures compared before and after addition of tiotropium are described in of systemic corticosteroids), 18 although we limited systemic corticosteroid use to an acute course of oral corticosteroids (OCS) accompanied by a lower respiratory consultation (physician visit coded as asthma, COPD, lower respiratory tract infection, or lung function/asthma monitoring, with further respiratory examination, thoracic radiographs, or referral). An acute respiratory event was defined as either an exacerbation or an antibiotic prescription accompanied by a lower respiratory consultation (which was taken to indicate that the physician treated the episode as a lower respiratory tract infection). Multiple qualifying events within a 2-week window were counted as a single exacerbation or acute respiratory event.
Secondary measures included the risk domain of asthma control (a proxy measure of asthma control as it pertains to exacerbation risk), specific components of the primary effectiveness measures (asthma-related acute OCS and antibiotic use), peak expiratory flow (PEF), forced expiratory volume in one second (FEV 1 ), the ratio of FEV 1 to forced vital capacity (FVC), and SABA usage. Asthma control in the risk domain was achieved if there were no episodes of asthma-related hospital, OCS, or antibiotic usage in the year of interest. As the measure of SABA usage, the prescribed SABA dosage was averaged over the year of interest, with all SABA dosages converted to salbutamol (albuterol) equivalents (Table S1 ).
statistical analysis
The statistical analysis was conducted using Summary statistics were generated for all baseline and outcome variables. The number of exacerbations in the year before and after initiating tiotropium was then compared using the Wilcoxon signed-rank test for exacerbation counts measured on the interval scale and the marginal homogeneity test for categorized exacerbation data. These tests were also used to compare baseline and outcome years for acute respiratory events, acute OCS courses, antibiotic prescriptions, and SABA usage. The paired t-test was used to compare baseline and outcome years for PEF and FEV 1 , and the marginal homogeneity test was used for comparison of categorized FEV 1 /FVC ratios. The proportion of patients achieving asthma control in the risk domain was compared between baseline and outcome years using the McNemar test.
sensitivity analysis
Although the selection process deliberately excluded asthma patients who also had a recorded diagnosis of COPD, some patients with undiagnosed or unrecorded COPD may have been included, given the average age of the study patients and the prevalence of current or former smokers. For this reason, the primary analyses (exacerbations and acute respiratory events) were repeated for a subset of patients who were unlikely to have COPD based on the following criteria: #40 years of age, .40 years of age but never smoked, and .40 years of age with no evidence of airway obstruction (baseline FEV 1 /FVC ratio $0.7).
Results
A total of 2,042 patients met the study criteria. The dry powder formulation of tiotropium was prescribed in 1,898 patients (93%) and the soft mist inhaler in 144 patients (7%). Key baseline patient characteristics are summarized in Tables 2 and 3 ; complete baseline data are provided in the Supplementary materials (Tables S2-S6 ). The mean age was 63 years; 59% of patients were female; the mean body mass index was 29 kg/m 2 ; and of those whose smoking history was known, 54% were either current (17%) or former (37%) smokers. In the patients with baseline lung function data, the mean PEF was 69% of predicted normal, the mean FEV 1 was 59% of predicted normal, and the mean FEV 1 /FVC ratio was 0.61; only 40% of the patients with FEV 1 and FVC data had a ratio $0.7.
At baseline, most patients were being treated according to British Thoracic Society guidelines 19 step 3 (21.5%) or step 4 (49.5%; Table S5 ). An ICS was prescribed in 83% of patients and a LABA in 68% of patients; 67% were prescribed both (Table S5 ). Median adherence to ICS therapy (Table S1) was 100%, with 51% of patients having $100% adherence (Table S5 ). The median controller-reliever ratio (Table S1) was 0.5, indicating approximately equal use of controller (ICS or leukotriene receptor antagonist) and reliever (SABA) medications, although 59% of patients had a ratio $0.5 (Table S5) , indicating relatively more controller than reliever use. During their baseline year, 37% of patients had at least one exacerbation, 58% had at least one acute respiratory event, and 41% achieved asthma control in the risk domain (Table 3) .
Outcomes
Comparisons between baseline and outcome years for the various effectiveness measures are summarized in Table 3 Journal of Asthma and Allergy 2015:8 submit your manuscript | www.dovepress.com
Dovepress

6
Price et al and illustrated in Figures 2-4 , with further details provided in Table S6 . Addition of tiotropium was associated with significantly fewer exacerbations ( Figure 2 ) and acute respiratory events ( Figure 3) ; 27% of patients had at least one exacerbation, 47% had at least one acute respiratory event, and 52% achieved asthma control in the risk domain during the outcome year (Table 3 ). In addition, tiotropium use was associated with significantly less asthma-related acute OCS and antibiotic use (Tables 3 and S6 ). Comparing baseline and outcome years, SABA usage significantly increased (Figure 4 ), but there were no significant changes in PEF, FEV 1 , or FEV 1 /FVC ratio in the patients with paired baseline and outcome data for those variables (Table 3) .
sensitivity analysis
The sensitivity analysis was conducted on 928 patients (45% of the full study group) with the least likelihood of also having COPD. Baseline characteristics are summarized in Table 4 , distributed by age group (#40 and .40 years). Compared with the full study group, proportionately more patients in this subset were female (65%) and nonsmokers (76%), and fewer were current (9%) or former (15%) smokers. The mean FEV 1 /FVC ratio was 0.8. The rates of exacerbations and acute respiratory events during the baseline year were comparable with those of the full study group, and the addition of tiotropium was associated with a similar decrease in exacerbations and acute respiratory events during the outcome year (Tables 5 and S7 ).
Discussion
Our study showed that primary care physicians in the UK have been prescribing LAMA for the treatment of asthma since 2002, even though there were no UK license or guideline recommendations for LAMA use in patients with asthma until September 2014. 15 It was not possible with our study design to determine why a LAMA was prescribed in these patients. However, 93% of the patients were over 40 years of age and 62% were over 60 years of age, more than 50% of whom were current or former smokers (Table S3 ). Most had significant comorbidities (Table S2) , and many had impairments of lung function and asthma control in the risk domain despite treatment with moderate to high doses of ICS ± LABA, $100% adherence to their ICS prescriptions, and controller-reliever ratios indicative of equal or greater use of controller medications throughout the year. Thus, it appears that physicians were prescribing LAMA predominantly as add-on therapy in older patients with poorly controlled asthma despite good treatment compliance, particularly in those who were current or former smokers.
In this population, addition of tiotropium was associated with a significant decrease in the incidence of exacerbations and other acute respiratory events (specifically, antibiotic prescriptions for lower respiratory tract infection), and a significant increase in the rate of asthma control in the risk domain over the following year. Whereas most of the aforementioned clinical trials emphasized current symptom control, our study was focused primarily on the effects of LAMA on the patient's exacerbation risk, as exacerbations have such a negative impact on the patient's quality of life and on health care resources. 20 The RCT by Kerstjens et al 3 showed a significant reduction in exacerbation risk with the addition of tiotropium; however, their patient population was younger than our study group by about 10 years (mean age, 53 years), 76% of their patients had never smoked, the remainder had a smoking history of ,10 pack-years, and none of their patients had serious coexisting illnesses. Thus, it may be particularly noteworthy that in our study LAMA therapy was associated with a decrease in exacerbations even under less-than-ideal conditions. Also of note, LAMA use in our study was associated with a significant reduction in acute OCS use, which may be expected to reduce the multifaceted treatment burden documented for corticosteroid use in patients with severe or poorly controlled asthma. 7 Given our study design, it may be argued that regression toward the mean could have contributed to the differences found between baseline and outcome years. This issue may have been obviated by using a matched control group not prescribed tiotropium, although such an approach would almost certainly have led to the loss of unmatched but otherwise qualified patients prescribed tiotropium and thus to a smaller number and perhaps less diverse group of patients for study. As it was, our study design involved data collected over 2 consecutive years within a continuum of ongoing therapy in long-term asthma patients that, for the group, spanned over a decade (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) ; and with the exception of the lung function indices, the baseline and outcome values each represented a full year of data, not repeated measures of single, isolated points in time. Thus, if regression toward the mean was a factor in our study results, its influence was likely small. Furthermore, our findings are supported by those of Kerstjens et al, 3 who showed in two replicate, randomized, double-blind, placebo-controlled, parallel-group clinical trials involving 48-week study periods and 912 patients in 15 countries that addition of tiotropium significantly increased the time to first exacerbation and decreased the exacerbation risk in patients whose asthma was poorly controlled despite maintenance treatment with ICS and LABA.
A legitimate concern, given our study design and patient demographics, is that the group may have included some asthma patients who also had undiagnosed or unrecorded COPD. The sensitivity analysis, limited to the patients least likely to have COPD, was conducted to address this issue. In this subset, addition of tiotropium was associated with decreases in the incidence of exacerbations and other acute respiratory events (specifically, antibiotic prescriptions for lower respiratory tract infection) similar to that found in the full study group. Thus, it is reasonable to conclude that LAMA therapy may be associated with a decrease in asthma exacerbations whether or not the patient may also have COPD.
A further criticism is that no separate control or comparator group was included, and treatment was not randomized. Our study purpose was to retrospectively examine the outcomes of clinical decisions made by primary care physicians with regard to the use of LAMA therapy in real-life patients with asthma. There was therefore no opportunity for us to randomize treatment, and as discussed above, our decision not to include a matched control group was made deliberately and with the goal of generating as large and diverse a 
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Price et al treatment group as possible. Thus, our study patients served as their own controls, the comparisons in asthma-related effectiveness measures being made between the year before and the year after initiating LAMA therapy. Despite this and other limitations imposed by our study design, our findings are generally consistent with those of the RCTs that included placebo 2,3,9-12 or comparator drug groups. 10, 13 Yet another potential shortcoming of our study design is that not all study patients had lung function data, and in those who did, no constraints could be placed on the timing of the lung function tests with regard to time of day (morning or evening) or bronchodilator administration (before or after bronchodilation), when the tests were performed in the outcome year relative to initiation of tiotropium therapy, nor on quality control of the measurements. In comparison, licensing studies require centralized spirometry over-reading to ensure high quality spirometry. In order to maximize patient numbers, we elected not to limit the study group to only those patients with paired lung function data. Physicians evidently were prescribing LAMA for patients with asthma even in the absence of lung function tests, so our full study group reflects recent clinical practices and outcomes.
The inability to dictate the timing and performance of the lung function tests in our study likely contributed to the large variations found in lung function values. Along with patient age and inclusion of smokers, that may explain the lack of significant changes in lung function with the addition of tiotropium, when improvements in lung function were a consistent RCT finding.
2,3,9-13 It is worth noting, however, that the RCT improvements in lung function with the addition of tiotropium, while statistically significant, often were small, and they were not consistently accompanied by improvements in asthma control or quality of life. 2, 3, 9, 12, 13 Between baseline and outcome years, the change in SABA usage in our study group, while statistically significant, was small and may be considered of little clinical relevance. This finding is consistent with RCT results for tiotropium use in patients with asthma, 2,3,10,13 but it is somewhat at odds with the classification of tiotropium as a long-acting bronchodilator that is administered once daily, 8, 15 and with the proposed mechanisms by which LAMA may improve asthma control. 1 A longer investigation period may be required to determine whether or not LAMA perform in practice as these mechanisms propose. In the meantime, it is useful to know that addition of tiotropium to the current treatment regimen may reduce the asthma patient's exacerbation risk within the first year of treatment.
Conclusion
In this real-life population of adults with asthma treated in routine clinical practice, addition of a LAMA to the current treatment regimen was associated with a decrease in exacerbations and other acute respiratory events (specifically, antibiotic prescriptions for lower respiratory tract infections) in the following year.
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Price et al Where ics prescribed, number of inhalers, dosage, and average daily dosage (averaged over the year); all ics dosages are in FP equivalents: large-particle BDP and budesonide dosages were divided by 2 to yield the FP-equivalent dosage; extra-fine particle BDP and ciclesonide dosages were considered directly equivalent to FP dosages for this study general practice consultations number of general practice consultations, total and asthma-related Adherence to ics therapy Adherence (%) = (total pack days ÷365) ×100; where total pack days = sum (number of days/pack), and days/pack = actuations/pack ÷ actuations/day controller-reliever ratio calculated as units of controllers ÷ (units of controllers + units of relievers); controllers included ics and lTrA, one unit = one inhaler for ics or one prescription for lTrA; relievers were limited to sABA, one unit = one inhaler; lABA were excluded from this analysis, as ics-lABA combination inhalers would have skewed the results
Supplementary materials
Notes:
a Date of the patient's first tiotropium prescription; e at least one asthma-related hospital visit during baseline year (categorized). Abbreviations: A&e, Accident and emergency Department; BTs, British Thoracic Society; ICS, inhaled corticosteroid; IPD, index prescription date (date of first tiotropium script); iQr, interquartile range; lABA, long-acting β 2 agonist; lTrA, leukotriene receptor antagonist; sAAc, short-acting anticholinergic; sABA, shortacting β 2 agonist.
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